A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 228 (planned)
- Started
- Nov 30, 2021
- Main results expected
- Mar 28, 2030
- Fully finished
- Mar 28, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose-Limiting Toxicities (DLTs)
Measured over: up to 21 days
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to 5 years
Incidence and severity of Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Incidence and severity of Adverse Events of Special Interest (AESIs)
Measured over: Up to 5 years
REGN4336 monotherapy concentrations in serum
Measured over: Up to 5 years
REGN4336 concentrations in serum in combination with REGN5678
Measured over: Up to 5 years
Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05125016 · record last updated 2026-05-05 · checked 2026-11-09 15:47 UTC